Veeva Systems (VEEV) 주식 개요
는 북미, 유럽, 아시아 태평양, 중동, 아프리카 및 라틴 아메리카의 생명 과학 산업을 위한 클라우드 기반 소프트웨어를 제공합니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 VEEV에 대한 위험이 감지되지 않았습니다.
VEEV Community Fair Values
Create NarrativeSee what 181 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Veeva Systems Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$161.55 |
| 52주 최고가 | US$310.50 |
| 52주 최저가 | US$148.05 |
| 베타 | 0.95 |
| 1개월 변동 | 1.34% |
| 3개월 변동 | -9.69% |
| 1년 변동 | -42.75% |
| 3년 변동 | -19.75% |
| 5년 변동 | -47.10% |
| IPO 이후 변동 | 334.74% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • Jun 01
VEEV: AI Moat And CRM Commitments Will Support Future Multiple Reacceleration
Narrative Update The analyst price target for Veeva Systems has been trimmed by about $2 to $262.68 as analysts factor in compressed software multiples, while largely maintaining their underlying growth, margin, and P/E assumptions. Analyst Commentary Recent research on Veeva Systems clusters around strong reported execution in Q4, tempered by valuation resets tied to compressed software multiples and longer term questions around AI and CRM competition.Seeking Alpha • May 29
Veeva Systems: Patience Required
Summary Veeva faces a critical Q1 earnings report after a 29% YTD share decline, with growth stabilization and AI progress in focus. VEEV's transition from Salesforce to Vault CRM and expansion of Crossix and the AI-driven Falcon platform are key strategic pivots. Guidance implies confidence: Q1 revenue $855–$858M, FY27 revenue $3.585–$3.60B, 44% margin, and strong free cash flow yield at 5.6%. Remain on the sidelines until clear signs of growth reacceleration; price target scenarios range from $127 to $210, depending on growth trajectory. Read the full article on Seeking Alpha내러티브 업데이트 • May 11
VEEV: AI Moat And CRM Commitments Will Support Premium Multiple
Veeva Systems' updated analyst price target edges lower to about $264 from roughly $265, as analysts keep their broadly positive take on the company's recent Q4 results but adjust valuation assumptions to reflect compressed software multiples and ongoing debates around AI, R&D growth, and CRM stability. Analyst Commentary Recent research on Veeva reflects a mix of optimism about execution in Q4 and caution around valuation and longer term growth drivers.내러티브 업데이트 • Apr 25
VEEV: AI Moat And Subscription Resilience Will Support Premium Multiple
Analysts have trimmed the Veeva Systems price target slightly, with the model fair value moving from about $270.93 to $264.46, as modestly lower assumed future P/E multiples more than offset largely unchanged growth and margin expectations. Analyst Commentary Recent Street research around Veeva Systems shows a split view, with many firms trimming price targets while still pointing to solid execution and specific areas of uncertainty that could influence the valuation over time.내러티브 업데이트 • Apr 08
VEEV: AI And Subscription Resilience Will Support Premium Software Multiple
Analysts trimmed the blended Veeva Systems price target by aligning with sector wide software multiple compression, even as they point to strong Q4 execution, resilient subscription growth, and an emerging AI and product pipeline as key longer term supports. Analyst Commentary Recent Street research around Veeva Systems reflects a mix of optimism on execution and growth, alongside more cautious views on competitive risk, AI impact, and valuation.내러티브 업데이트 • Mar 25
VEEV: AI Adoption In R&D Workflows Will Support Durable Premium Outlook
Analysts have adjusted their price targets on Veeva Systems into a roughly $190 to $317 range, generally trimming prior targets by tens of dollars as software valuation multiples compress, even after what they describe as solid Q4 results and broadly constructive longer term fundamentals. Analyst Commentary Recent research paints a mixed but generally constructive picture for Veeva Systems, with most firms trimming price targets while still pointing to solid execution and durable fundamentals.내러티브 업데이트 • Mar 11
VEEV: AI Adoption And CRM Commitments Will Support Durable Premium Outlook
We are trimming our Veeva Systems fair value estimate to $270.93 from $302.60, as analysts broadly reset price targets in response to sector wide software multiple compression and slightly more measured assumptions for revenue growth, margins, and future P/E multiples, despite generally solid Q4 results and guidance. Analyst Commentary Street research on Veeva Systems has become more mixed, with many firms cutting price targets while still acknowledging solid Q4 execution and robust profitability.내러티브 업데이트 • Feb 25
VEEV: AI Execution And CRM Stability Will Support Durable Premium Outlook
Our fair value estimate for Veeva Systems has edged down from $308.63 to $302.60. This reflects a series of reduced Street price targets as analysts weigh maturing products, competitive pressures, software sentiment, and the balance of growth opportunities against current valuation.내러티브 업데이트 • Feb 10
VEEV: Roche Commitment And CRM Retention Will Support Durable Premium Outlook
Our analyst fair value estimate for Veeva Systems has been trimmed slightly to $308.63. This reflects a modest reset in Street price targets as analysts balance concerns about slower growth in maturing products and competitive pressure with ongoing strengths in areas like Crossix, AI adoption, and large CRM wins such as Roche.
새로운 내러티브 • Jan 28
Rising Life Sciences Cloud Standardization And AI Adoption Will Support Strong Long Term Upside
Catalysts About Veeva Systems Veeva Systems provides cloud based software, data and consulting services to life sciences companies across commercial, R&D and manufacturing functions. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Jan 27
VEEV: Roche Rollout And CRM Retention Will Support Durable Premium Outlook
The analyst price target embedded in our Veeva Systems model edges slightly lower to about US$310 from roughly US$311. This reflects a blend of more cautious views on growth and competitive pressure, along with offsetting positive views on durable margins, CRM customer retention, and newer areas such as Crossix and early AI traction.내러티브 업데이트 • Jan 12
VEEV: Roche Expansion And CRM Migrations Will Support Durable Premium Outlook
Analysts have trimmed their fair value estimate for Veeva Systems by about US$1 to US$310.98, reflecting modest adjustments to discount rate and growth assumptions while still pointing to what they see as durable growth drivers such as pharma CRM migrations, broader Vault adoption and newer areas like Crossix and AI. Analyst Commentary Recent Street research on Veeva Systems reflects a mix of optimism and caution, with differing views clustering around the durability of growth in CRM and Vault, the timing of pharma migrations, and how current valuation stacks up against execution and contract wins.내러티브 업데이트 • Dec 19
VEEV: Roche Commitment And CRM Migrations Will Likely Sustain Premium Outlook
Analysts have modestly trimmed their blended price target for Veeva Systems to about $312 from roughly $321, reflecting a slightly higher discount rate and lower implied future multiple, even as they highlight accelerating CRM migrations, including Roche's global Vault CRM rollout, and improving long term growth and margin expectations. Analyst Commentary Street research remains broadly constructive on Veeva Systems, with recent target changes reflecting a recalibration of software multiples rather than a material shift in company specific fundamentals.분석 기사 • Dec 03
Veeva Systems' (NYSE:VEEV) Performance Is Even Better Than Its Earnings Suggest
Investors were underwhelmed by the solid earnings posted by Veeva Systems Inc. ( NYSE:VEEV ) recently. We have done...내러티브 업데이트 • Nov 11
VEEV: Continued Momentum And New Commitments Will Likely Sustain Premium Outlook
Analysts have significantly raised their price targets on Veeva Systems, with recent updates moving targets as high as $380. They cite the company's strong sales growth prospects and solid momentum, driven by accelerating CRM customer commitments and new partnerships.내러티브 업데이트 • Oct 27
Pharma Wins And New Partnerships Will Drive Cloud Momentum In Coming Quarters
Veeva Systems' analyst price target saw a significant increase, rising by more than $80 to reflect higher expectations for sales growth and ongoing customer commitments. Analysts cited the company’s strengthening position in CRM and positive momentum across key pharma relationships.내러티브 업데이트 • Oct 13
IQVIA Resolution And Embedded AI Will Expand Digital Healthcare Cloud
Narrative Update on Veeva Systems: Analyst Price Target Revision Analysts have raised their fair value estimate for Veeva Systems to approximately $321 per share, up by nearly $4. They cited stronger than expected sales momentum, driven by new major customer commitments and continued growth in key business segments.내러티브 업데이트 • Aug 29
Data Cloud Expansion And AI Efficiencies Will Drive Future Success
Analysts have raised their price target for Veeva Systems to $314.71, citing strong Q2 “beat and raise” results, momentum in both Commercial and R&D segments, successful Vault CRM rollouts with major pharma clients, and ongoing market share gains in life sciences CRM. Analyst Commentary Bullish analysts highlighted Veeva's strong “beat and raise” Q2 results, with both subscription and services revenues growing solidly year-over-year, driven by performance in both Commercial and R&D technology segments.분석 기사 • Jul 11
If EPS Growth Is Important To You, Veeva Systems (NYSE:VEEV) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Apr 17
Veeva Systems: Substantially Overvalued As Growth Slows
Summary Veeva Systems is overvalued, trading at frothy levels despite only ~10% growth, and facing a potential slowdown in 2025; I recommend a sell rating. The company excels in the life sciences vertical with unique solutions but its ambitious revenue targets (doubling revenue by 2030) may be tough to achieve organically. Valuation multiples are high at ~10 EV/FY26 revenue and ~30x FY26 P/E, well above a number of peers - some of which are growing even faster than Veeva. Read the full article on Seeking AlphaSeeking Alpha • Mar 19
Veeva Systems: Staying Buy Rated As VEEV Is Executing Well
Summary I reaffirm my buy rating on Veeva Systems due to strong 4Q25 results, driven by R&D growth and positive Vault CRM adoption traction. VEEV's revenue grew 14% y/y to $721 million, beating expectations, with significant margin improvements and a strong balance sheet. Vault CRM added 20 new customers, with multiple top 20 pharma commitments expected in 2025, signaling positive transition progress. Data Cloud segment shows strong momentum, with new initiatives like Pulse expected to drive further CRM adoption and growth. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Veeva Systems: Solid Q4 With Margin Expansion
Summary I reiterate my “Strong Buy” rating on Veeva Systems Inc. with a one-year target price of $275 per share due to strong CRM migration and margin improvement. Veeva reported 14.3% revenue growth and 28.7% adjusted operating profit growth, driven by robust CRM adoption and billing growth. Management's guidance for FY26 includes $3.04-$3.055 billion in revenue, with anticipated 12% revenue growth despite high-interest rate challenges. I foresee continued margin expansion and revenue growth recovery to 16% by FY27 for VEEV, supported by CRM migration and easing capital funding challenges. Read the full article on Seeking AlphaSeeking Alpha • Jan 28
Veeva Systems: Forget The Short-Term Volatility; The Long Term Is Promising
Summary I rate Veeva Systems as a 'Buy' due to its strong performance recovery, despite competition from Salesforce and industry uncertainties under Trump's administration. VEEV's migration to its own CRM, Veeva Vault, is a long-term tailwind, enhancing its ecosystem and competitive edge. The Company's Q3 2025 results exceeded expectations, with significant revenue, net income, and free cash flow growth, raising FY 2025 guidance. Despite short-term volatility, Veeva's specialization in life sciences, strong balance sheet, and innovative culture position it well for long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Dec 06
Veeva Systems Q3: Making Progress With Vault CRM; Reiterating 'Strong Buy'
Summary Veeva Systems shows strong growth with 13.4% revenue and 30% adjusted operating income increases, driven by successful Vault CRM migration and new customer acquisitions. The company is expanding AI offerings within Vault CRM, including CRM Bot, GenAI assistant, and Voice Control, enhancing customer experience and retention. VEEV's FY25 revenue growth is projected at over 15%, with a one-year target price of $270 per share, supported by a stable funding environment. Despite a one-time revenue recognition impact due to TFC rights, Veeva's long-term outlook remains positive, reinforcing my 'Strong Buy' rating. Read the full article on Seeking AlphaSeeking Alpha • Oct 08
Veeva Systems: Too Much Needs To Go Right, For Bull Case
Summary I appreciate Veeva Systems’ strong cash position and debt-free balance sheet, which provide stability and strategic flexibility. I recognize Veeva’s leadership in life sciences software, offering specialized solutions that streamline R&D and commercial operations. I see the migration to Vault CRM as a pivotal moment for the company, but I am wary of customer resistance that could impact growth. I acknowledge that Veeva’s path to higher profitability hinges on flawless execution, making it a high-risk, high-reward scenario. Read the full article on Seeking AlphaSeeking Alpha • Sep 24
Veeva Systems: SMB Sector Is Growing Momentum
Summary I rate Veeva Systems Inc. as a buy due to the recent 0.5% interest rate cut from the FED, boosting demand from recovering SMB biotech firms. Veeva's Q2 FY2025 results exceeded expectations, with revenue reaching $676 million and subscription revenue hitting $561 million, ensuring stable free cash flow. Improved FY2025 guidance, with revenue and non-GAAP operating earnings projections slightly raised, is positively influencing market sentiment. Veeva's revenue growth of 18.8% YoY and net income growth of 7.38% YoY demonstrate profitable expansion, supporting a strong long-term investment thesis. Read the full article on Seeking Alpha주주 수익률
| VEEV | US Healthcare Services | US 시장 | |
|---|---|---|---|
| 7D | -9.5% | -5.7% | -4.1% |
| 1Y | -42.7% | -47.7% | 20.6% |
수익률 대 산업: VEEV은 지난 1년 동안 -47.7%의 수익을 기록한 US Healthcare Services 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: VEEV은 지난 1년 동안 20.6%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| VEEV volatility | |
|---|---|
| VEEV Average Weekly Movement | 6.5% |
| Healthcare Services Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: VEEV는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: VEEV의 주간 변동성(6%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2007 | 7,928 | Peter Gassner | www.veeva.com |
는 북미, 유럽, 아시아 태평양, 중동, 아프리카 및 라틴 아메리카의 생명 과학 산업을 위한 클라우드 기반 소프트웨어를 제공합니다. 이 회사는 제약 및 생명공학 기업을 위한 Veeva Vault CRM Suite, 여러 채널과 지역에 걸쳐 의료 콘텐츠 소스를 제공하는 Veeva Medical, 엔드투엔드 콘텐츠 및 디지털 자산 관리 솔루션인 Veeva PromoMats, 제약 브랜드를 위한 분석 플랫폼인 Veeva Crossix 등으로 구성된 Veeva Commercial Cloud를 제공합니다. 또한 고객 참조 데이터 솔루션인 비바 오픈데이터, 심층 데이터를 제공하는 비바 링크, 비식별화된 종단적 환자 데이터를 포함하는 비바 컴파스, 액세스 및 멀티채널 참여 지표를 제공하는 비바 CRM 펄스 등 비바 데이터 클라우드(Veeva Data Cloud)를 제공합니다.
Veeva Systems Inc. 기초 지표 요약
| VEEV 기초 통계 | |
|---|---|
| 시가총액 | US$26.60b |
| 순이익 (TTM) | US$941.65m |
| 매출 (TTM) | US$3.32b |
27.9x
주가수익비율(P/E)7.9x
주가매출비율(P/S)VEEV는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| VEEV 손익계산서 (TTM) | |
|---|---|
| 매출 | US$3.32b |
| 매출원가 | US$829.12m |
| 총이익 | US$2.49b |
| 기타 비용 | US$1.55b |
| 순이익 | US$941.65m |
최근 보고된 실적
Apr 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 5.80 |
| 총이익률 | 75.02% |
| 순이익률 | 28.37% |
| 부채/자본 비율 | 0% |
VEEV의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/11 01:23 |
| 종가 | 2026/06/11 00:00 |
| 수익 | 2026/04/30 |
| 연간 수익 | 2026/01/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Veeva Systems Inc.는 44명의 분석가가 다루고 있습니다. 이 중 28명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Joseph Vruwink | Baird |
| Saket Kalia | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |